Impact of Calcium Fructoborate on WOMAC and McGill Subscales and Individual WOMAC Questions: Post-Hoc Analyses of Data from a Previously Published 90-Day Randomized Clinical Trial


  • Jennifer Robinson Auburn University
  • Boris Nemzer
  • Tania Reyes-Izquierdo
  • Zbigniew Pietrzkowski
  • John Hunter



cfb, calcium fructoborate, FruiteX-B, WOMAC, McGill, osteoarthritis, knee discomfort, knee pain


Calcium fructoborate (CFB) has been shown to reduce overall joint discomfort on the Western Ontario and McMaster University Arthritis Index (WOMAC) and the McGill Pain Questionnaire (MPQ). No study has addressed the impact of CFB on the subscales of these measures, nor on individual questions. Here, we re-examined data from a previously peer reviewed and published 90-day, double-blind, randomized, placebo-controlled study on CFB to determine whether there were subscale or individual questions differences. In the original study participants were randomized into three groups: 1) placebo, 2) a morning dose of 216mg of CFB and evening dose of placebo (CFB1), or 3) a morning and evening dose of 108mg of CFB (CFB2). Our new analyses indicated that by day 30, both CFB groups were distinguishable from placebo on the WOMAC Pain and WOMAC Activities of Daily Living subscales. Furthermore, they were distinguishable from the WOMAC Stiffness subscale by days 60 and 90 (CFB1, CFB2, respectively). Importantly, analyses of individual WOMAC questions revealed differences in at little as 14 days. For the McGill pain subscale, differences emerged by day 7 and 14 between placebo and CFB1/CFB2 groups, respectively, while the affective dimension was different from CFB groups by day 60. For the miscellaneous dimension, placebo was differentiable by day 60 and 90 (CFB1/CFB2, respectively). These data provide greater visibility into CFB’s joint health benefits and suggest that CFB’s effects support real improvements in practical aspects of daily physical activity.


] Nguyen, U.-S.D.T., et al., Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis: Survey and Cohort Data. Annals of Internal Medicine, 2011. 155(11): p. 725-732.

] Kim, I.J., et al., Prevalence of Knee Pain and Its Influence on Quality of Life and Physical Function in the Korean Elderly Population: A Community Based Cross-Sectional Study. J Korean Med Sci, 2011. 26(9): p. 1140-1146.

] Cui, A., et al., Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine, 2020. 29-30: p. 100587.

] Turck, D., et al., Safety of calcium fructoborate as a novel food pursuant to Regulation (EU) 2015/2283. EFSA journal. European Food Safety Authority, 2021. 19(7): p. e06661-e06661.

] Pietrzkowski, Z., et al., Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. Clinical Interventions in Aging, 2014. 9: p. 895-899.

] Pietrzkowski, Z., et al., Effects of once-daily versus twice daily dosing of calcium fructoborate on knee discomfort: A 90 day, double-blind, placebo-contolled randomized clinical study. J Aging Research and Clinical Practice, 2018. 7: p. 31-36.

] Scorei, R., et al., A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res, 2011. 144(1-3): p. 253-263.

] Scorei, I.D. and R.I. Scorei, Calcium Fructoborate Helps Control Inflammation Associated with Diminished Bone Health. Biological Trace Element Research, 2013. 155(3): p. 315-321.

] Price, A.K., et al., Effects of dietary calcium fructoborate supplementation on joint comfort and flexibility and serum inflammatory markers in dogs with osteoarthritis1,2. Journal of Animal Science, 2017. 95(7): p. 2907-2916.

] Scorei, R.I., et al., In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res, 2010. 135(1-3): p. 334-344.

] Scorei, R., V.M. Cimpoiasu, and D. Iordachescu, In vitro evaluation of the antioxidant activity of calcium fructoborate. Biological Trace Element Research, 2005. 107(2): p. 127-134.

] Scorei, R., et al., In vitro effects of calcium fructoborate on fMLP-stimulated human neutrophil granulocytes. Biol Trace Elem Res, 2007. 118(1): p. 27-37.

] Scorei, R.I. and P. Rotaru, Calcium Fructoborate—Potential Anti-inflammatory Agent. Biological Trace Element Research, 2011. 143(3): p. 1223-1238.

] Văruţ, R.M., et al., Calcium fructoborate coating of titanium-hydroxyapatite implants by chemisorption deposition improves implant osseointegration in the femur of New Zealand White rabbit experimental model. Rom J Morphol Embryol, 2020. 61(4): p. 1235-1247.

] Hussain, S.A., S.J. Abood, and F.I. Gorial, The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. Journal of intercultural ethnopharmacology, 2016. 6(1): p. 58-64.

] Miljkovic, D., et al., Calcium Fructoborate: Plant-Based Dietary Boron for Human Nutrition. Journal of Dietary Supplements, 2009. 6(3): p. 211-226.

] Aysal, H., N. Atasoy, and A.U. Kömüroğlu, Protective Effect of Calcium Fructoborate Against Carbon Tetrachloride–Induced Toxicity in Rats. Biological Trace Element Research, 2022.

] Scorei, R., et al., Comparative Effects of Boric Acid and Calcium Fructoborate on Breast Cancer Cells. Biological Trace Element Research, 2008. 122(3): p. 197-205.

] Scorei, I.R., Calcium fructoborate: plant-based dietary boron as potential medicine for cancer therapy. FBS, 2011. 3(1): p. 205-215.

] Bellamy, N., et al., Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. (0315-162X (Print)).

] Hawker, G.A., et al., Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care & Research, 2011. 63(S11): p. S240-S252.

] Melzack, R., The McGill Pain Questionnaire: Major properties and scoring methods. PAIN, 1975. 1(3): p. 277-299.

] Collins, N.J., et al., Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. Osteoarthritis and Cartilage, 2016. 24(8): p. 1317-1329.

] Roos, E.M. and L.S. Lohmander, The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health and Quality of Life Outcomes, 2003. 1(1): p. 64.




How to Cite

Robinson, J., Nemzer, B., Reyes-Izquierdo, T., Pietrzkowski, Z., & Hunter, J. (2023). Impact of Calcium Fructoborate on WOMAC and McGill Subscales and Individual WOMAC Questions: Post-Hoc Analyses of Data from a Previously Published 90-Day Randomized Clinical Trial. European Journal of Applied Sciences, 11(1), 319–340.